Westlake Genetech Invited to Present at 2025 ESGCT Annual Meeting

Westlake Genetech has been invited to attend and deliver an on-site presentation at the 32nd Annual Meeting of the European Society of Gene and Cell Therapy (ESGCT), to be held at Fibes in Seville, Spain, from October 7 to 10, 2025 (local time).

Presentation Core Information

• Date & Time: October 07, 2025, 18:45 (Local Time)
• Venue: Franciscan B (Ballroom Level), Hilton San Francisco - Union Square
• Speaker: Dr. Ma Lijia, Founder of Westlake Genetech
• Presentation Title: An AAV6 variant engineers human resting T cells in vivo

The 32nd Annual Congress of the European Society of Gene and Cell Therapy (ESGCT) will be held in Seville, Spain, from October 7 to 10, 2025. Dr. Lijia Ma, founder of Westlake Genetech, will share Westlake Genetech's latest progress in in vivo CAR-T therapy with global experts and scholars.

About the ESGCT Annual Congress

As one of the most authoritative international academic events in gene and cell therapy, it gathers researchers, scientists, clinicians, and industry experts worldwide to exchange cutting-edge research findings, technological breakthroughs, and clinical translation applications. The conference features academic presentations, poster sessions, symposia, and networking activities, fostering communication and collaboration to advance the gene and cell therapy field.

About Westlake Genetech

Westlake Genetech is an innovative biotech company focused on leveraging AI to accelerate the research and development of next-generation gene therapies. Through the proprietary gene therapy technology platforms, the company has achieved significant technological breakthroughs in capsid engineering and payload redesigning, including novel AAV variants with tropism for T cells, CNS and muscle tissues, as well as optimized gene-editing tools. These innovations will help drive the development of safer, more accessible and more efficient gene therapies to address more unmet needs.

Contacts: bd@westlakegenetech.com